Filing Flows › Aligos Therapeutics (ALGS) › Q4 2025
Aligos Therapeutics (ALGS) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 5, 2026
Aligos Therapeutics (ALGS) reported revenue of $169K for the fourth quarter 2025 (Q4 2025), -72% from a year earlier and -77% from the quarter before.
Aligos Therapeutics, Q4 2025: revenue $169K (-72% year over year), net loss $19.9M, operating cash flow −$21.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $169K | -77% | -72% |
| Operating profit | −$21.8M | — | — |
| Net earnings | −$19.9M | — | — |
| Operating cash flow | −$21.7M | — | — |
What changed
Revenue was $169K in Q4 2025, down 72% year over year and down 77% from the previous quarter.
Operating costs exceeded revenue by $21.8M, an operating margin of -12907.7%. Total costs grew 4% against a revenue fall of 72%. The quarter ended with a net loss of $19.9M, narrower than the previous quarter's $31.5M loss.
Operating cash flow was −$21.7M. Non-cash charges added back $257K of depreciation and $1.5M of share-based compensation. Working capital and other items used $3.6M.
Questions
What was Aligos Therapeutics' revenue in the fourth quarter 2025?
Aligos Therapeutics (ALGS) reported revenue of $169K for the fourth quarter 2025 (Q4 2025), -72% from a year earlier and -77% from the quarter before.